Login to Your Account



Bulls Proved Right: Hyperion's Ravicti Wins Approval in UCD

By Jennifer Boggs
Managing Editor

Monday, February 4, 2013
The recent spike in Hyperion Therapeutics Inc.'s stock proved to be warranted Friday, when the FDA issued an approval for Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients, ages 2 and older.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription